Biotech

All Articles

Analysts examine Avidity's DMD succeed, exposing subtleties in records

.Avidity Biosciences impressed investors along with stage 1/2 records in Duchenne muscular dystrophy...

Actinogen's cortisol blocker neglects phase 2 anxiety study

.Actinogen Medical's cortisol blocker has missed the major endpoint of a period 2 research in clinic...

Bivictrix decides going private only means to take ADC into facility

.Antibody-drug conjugates (ADCs) have actually gone to the center of several a billion-dollar biobuc...

TPG leadings up funds to $580M for investments around life scientific researches

.Resource manager TPG, which has actually assisted biotechs including Sionna Therapies and Santa Cla...

Merck stops stage 3 TIGIT test in lung cancer cells for impossibility

.Merck &amp Co.'s TIGIT system has actually experienced another setback. Months after shuttering a s...

After a challenging year, Exscientia folds into Recursion

.After a year described by pipeline cuts, the departure of its own CEO and cutbacks, Exscientia is g...

Cullinan, after $25M bargain, hands back bispecific to Harbour

.Cullinan Therapy was excited enough with Harbour BioMed's bispecific invulnerable reactor that it e...

A nearer check out Ferocious Biotech's Tough 15

.In this week's episode of "The Leading Line," our experts're diving into Fierce Biotech's annual St...

Lilly experiences stage 2 failure of tau-targeting med

.The confetti is still soaring from Eli Lilly's party celebrating the commendation of Alzheimer's di...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our summary of significant leadership hirings, firings a...